Clinical Study of First-line Treatment of Small Cell Lung Cancer (SCLC) With Anlotinib Hydrochloride

• Status: Unknown status
• Trial end date: 2020-10-01
• Target enrollment: 0
• Participant gender: All

Summary

This study was designed to investigate the efficacy and side effects of combining erlotinib with classical EC/EP chemotherapy regimens.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Chifeng Municipal Hospital

Criteria

Inclusion Criteria:

1. patients 18-75 years of age.

2. A metastatic or recurrent advanced SCLC confirmed by histology or cytology and did not receive any other treatment;

3. a measurable disease

4. an Eastern Cooperative Oncology Group PS of 0-1;

5. an estimated survival duration of >6 months;

Exclusion Criteria:

1. Have used erlotinib or other anti-vascular targeted drugs (eg, Endo, bevacizumab, etc.)2. Patients who have been treated with chemotherapy or radiotherapy for previous tumors.3.Have appeared or merged with other tumors within 5 years.4.Patients with no measurable lesions; 5.any severe and uncontrolled disease.